The use of autologous fat transfer (AFT) or lipofilling for correcting contour deformities is seen as one of the major breakthroughs in reconstructive plastic surgery. Its applications in facial reconstructive surgery have been of particular interest owing to the prospect of achieving autologous reconstruction by a minimally invasive approach. However, its unpredictability and variable degree of resorption have limited its utility and much skepticism still exists regarding its efficacy. Furthermore, more than 2 decades of clinical research have produced a highly fragmented body of evidence that has not been able to provide definite answers.
A utologous fat transfer (AFT), also known as lipofilling or fat grafting, is regarded as an elegant technique that excels in correcting soft-tissue contour deformities and volume deficits in almost any body part. Its application in the face has always been of particular interest because it allows for precise titration and injection of the patient's own fat by means of a minimally invasive approach. Autologous fat transfer can play an important role in the treatment of disfiguring congenital syndromes such as progressive hemifacial atrophy (Parry-Romberg syndrome) or hemifacial (craniofacial) microsomia. For these disorders, the only viable alternative for correcting volume deficits remains the free-flap transfer, which often leads to disappointing results in the long term due to sagging and disruption of facial musculature. Another disorder that can greatly benefit from AFT is human immunodeficiency virus (HIV)-associated lipodystrophy, where antiretroviral therapy can lead to devastating facial wasting. The prospect of restoring facial volume without relying on allogenic fillers of implants makes AFT a promising solution in these patients. Owing to these properties, fat transfer has also been increasingly applied in the treatment of acquired soft-tissue defects in the face such as adhesive scars and even burns ( Figure 1) .
However, the unpredictability of long-term graft retention has hampered the widespread acceptance and application of AFT in reconstructive plastic surgery. The loss of a significant portion of the grafted volume seems to be an inherent limitation with AFT, which has been the main criticism with this technique. This has engendered divergent and even polarized opinions among plastic surgeons worldwide with respect to whether AFT offers a reliable solution for correcting soft-tissue deformities in facial reconstructive surgery. Unfortunately, more than two decades of clinical research have failed to provide convincing evidence on this matter. The reason is that published literature comprises of a large number of small studies investigating a diversity of outcome measures in different patient populations, producing a body of evidence that is highly fragmented and difficult to analyze.
This has inspired us to perform the first systematic review and meta-analysis on the subject, aimed to facilitate interpretation of the evicence on the efficacy and safety of AFT in facial reconstructive surgery by clinicians, guideline committees, and policy makers.
Methods
This systematic review adhered to the standards of the Cochrane Handbook of Systematic Reviews of Interventions 1 and the Meta-analysis Of Observational Studies in Epidemiology 2 and was written in the format provided by the Preferred Reporting Items of Systematic Reviews and Meta-Analyses (PRISMA) statement 3 (eTable 1 in the Supplement). A comprehensive, reproducible electronic search was conducted in PubMed, Embase, and the Cochrane Library to identify all published studies with human subjects receiving AFT for facial reconstruction (eTables 2 and 3 in the Supplement). The search was performed on October 11, 2017. Eligibility assessment was performed in a standardized manner. The retrieved hits were screened and reviewed by 2 independent reviewers (T.K.K. and J.B.) based on the title and abstract using predefined inclusion and exclusion criteria. Disagreements were solved through discussion until consensus was reached. An additional assessment was performed based on the full-text versions of all selected records and those with insufficient information in the
Key Points
Question Is autologous fat transfer (lipofilling) a safe and effective treatment for soft-tissue deformities in the face?
Findings This systematic review and meta-analysis of 52 studies and 1568 patients found autologous fat transfer to be associated with a high patient satisfaction rate (91.1%) and surgeon satisfaction rate (88.6%) after 1.5 sessions. Volume retention stabilized at 50% to 60% at 1 year, and only 4.8% of procedures resulted in clinical complications.
Meaning This meta-analysis of the combined data from all published studies confirms that autologous fat transfer is a safe and effective treatment in facial reconstructive surgery. To be able to conduct a meta-analysis, a thorough extraction of all relevant data was performed (eTable 4 in the Supplement). In some occasions, authors were contacted to send additional data. In cases when key data was reported only in graphs or figures, it was extracted using the WebPlotDigitizer software.
4 Whenever necessary, units were transformed to a standard format to ensure comparability and allow pooling of data. Continuous variables reported in the form of median (range) were transformed into mean (SD) using the standard estimating equations used for meta-analyses. 5 Custom outcome measurement scales and scores were also standardized accordingly. Finally, if studies from the same author or institution conducted in the same time period and reporting the same outcomes were suspected for overlap of more than 25% of the sample size, only the largest or most relevant study was included. Meta-analysis was performed using the metafor package 6 of the R software (R Project). 7 Summary measures were pooled in a standard random-effects model and presented as forest plots. Heterogeneity was assessed using the I 2 statistic, which was tolerable if below 50%. Publication bias considered acceptable if on visual inspection the distribution of studies was approximately symmetrical.
Results

Study Selection
The electronic search yielded a total of 370 unique hits ( Figure 2) . Screening of the title and abstract lead to the inclusion of 102 studies for further evaluation. A total of 43 clinical trials were selected through further screening of the full-text. Reasons for exclusion consisted of the unavailability of the full text, secondary sources (reviews, commentaries), the use of AFT for cosmetic indication and enhancement with supplements (such as plateletrich plasma or stromal-vascular fraction). Case reports (defined as reports of 5 cases or fewer) were also not considered for inclusion. Screening of the citations, references, and related articles of the 43 selected trials yielded 9 additional hits. It should be noted that some cohort studies consisting of 1 or more treatment arms, which did not meet the inclusion criteria of the predefined PICO (patient/problem/population, intervention, comparison/ control/comparator, outcome) process, such as use of supplements or combination treatments, were not included in the analysis. This was also the case whenever outcomes of interest were only relevant or measured in one of the treatment groups.
Study Characteristics
Fifty-two clinical trials were identified for inclusion (eTable 5intheSupplement). They consisted of 37 case series, 11 cohort studies, and 4 randomized clinical trials. The majority of these had a retrospective design (n = 44), and all studies were conducted between January 1986 and December 2016.
Population
From the 52 included studies (1549 patients), only 1 study was suspected of significant overlap in patient populations, 45 resulting in 51 studies with a total of 1533 unique patients. Most commonly, a study would include patients of a specific diagnosis. In fourteen studies, 11, 12, 17, 19, 20, 23, 33, 35, 37, 38, 44, 45, 49, 54 it involved patients with HIV-associated lipodystrophy, comprising 650 patients, thus representing the most common indication for which AFT is decribed in published literature. The majority of patients with HIV-associated lipodystrophy (n = 500 of 650 [76.9%]) were men, and the mean age at the time of the first AFT session was 42.6 years (95% CI, 34.4-46.7). Furthermore, 16 studies 10, [14] [15] [16] 25, 26, 28, 32, 43, 47, 50, 52, 53, [57] [58] [59] consisting of 409 patients evaluated AFT in patients with congenital disorders. From this group, 201 (49.1%) patients suffered from Parry-Romberg syndrome, 181 (44.3%) from craniofacial microsomia, and the remaining 27 patients (6.6%) represent a mixed group of craniofacial microsomia, Goldenhar syndrome, and Treacher Collins from a single study. 32 The mean age at the time of treatment with AFT was 23.8 years (95% CI, 19.8-27.8) in this group. Another 17 studies 8, 9, 13, 18, 21, 22, 24, 27, 29, 30, [39] [40] [41] 46, 48, 55, 56 formed a more heterogeneous group consisting 326 patients with a mean age of 36.8 years (95% CI, 31.5-42.1) treated with AFT for a variety of acquired facial deformities. In 7 studies, AFT was 
Intervention
From the included trials, the vast majority adhered to the principles of AFT as described by Coleman, 60 with the occasional minor variation in the surgical instruments used.
Control Group
Only 16 studies examining AFT included a control group, which most often involved patients receiving AFT with supplements (n = 9) such as platelet-rich plasma, 
Outcome Measures
The satisfaction of the patient with respect to the result of the AFT reconstruction was measured in 30 trials. Twelve of these studies presented the result using categorical or Likert scores and reported the number of patients with a certain score (category) at the end of the treatment. The Likert scales consisted of a scale with 2 to 5 categories corresponding to degrees of satisfaction with the outcome (eg, very dissatisfied, dissatisfied, satisfied, very satisfied) or opinion about the rate of improvement (eg, very poor, poor, fair, good, excellent). To standardize the scales, scores were dichotomized into 2 distinct categories-satisfied vs dissatisfied. For all studies, such a cut-off point between the positive and negative categories was easily identifiable. Furthermore, 22 studies presented satisfaction scores in the form of custom-made visual analog scales (VAS), ranging from 4 to 50 levels, which were transformed into a standard 10-point VAS scale (0 = maximum dissatisfaction, 10 = maximum satisfaction).
Surgeon Satisfaction and/or Evaluation
Twenty-nine studies reported the surgeon's satisfaction, which typically consisted of visual evaluation of preoperative and postoperative photographs to determine the rate of success of the AFT treatment. Sixteen studies reported surgeon's evaluation using Likert scales with 2 to 5 categories describing the effect of AFT on the clinical result, which were subsequently dichotomized into good vs poor. Ten studies reported mean VAS scores (range 0-3 to 0-20), and these were also transformed to a standard scale from 0 (very poor result) to 10 (excellent result).
Volume Measurements
From 16 studies addressing fat resorption through volume measurements, 3 attempted to estimate volume changes by evaluating tissue thickness using ultrasonography or computed tomography (CT) scan and were excluded from the analysis. 8, 16, 48 The remaining 13 studies used appropriate imaging techniques, such as 3-dimensional image capture devices 25, 28, 36, 50, 53, 58 or CT. 14, 19, 20, 43, 52 Eight of these investigated volume retention in exclusively congenital patients (Parry-Romberg and craniofacial microsomia), while the remaining 5 involved patients with HIV-associated lipodystrophy. The percentage graft retention represents the fraction of the measured gain in volume, relative to the total volume of injected fat. The relationship between the graft retention and time (follow-up length) was investigated by means of a meta-regression.
AFT-Related Complications
Forty-five studies evaluated the safety of AFT in terms of immediate and late AFT-related complications. A total of 65 complications were documented in 1755 AFT procedures (3.7%), with the majority consisting of irregularities or asymmetry post-AFT (chiefly in patients with HIV). Only 2 infections (0.1%), 2 cases of fat necrosis, (0.1%) and 10 hematomas (0.6%) were reported, and these represent the only true complications encountered in this vast cohort. Additional meta-analysis was performed to derive the proportion of complications per AFT procedure.
Time Frame and Meta-analysis Results
The average clinical follow-up after AFT was 1.3 years (95% CI, 0.9-1.6). Results of individual studies are presented in eTable 4intheSupplement. A random-effects model meta-analysis was performed with pooled data of each outcome. Categorical data was dichotomized and presented as a meta-analysis of proportions, which can be treated as percentages.
Patient Satisfaction
Meta-analysis of categorical data revealed an overall proportion of satisfied patients of 91.1% (95% CI, 85.4%-94.8%), after a mean follow-up of 2.0 years ( Figure 3 ). It was highest in studies with mixed patients (95.9%), followed by patients with HIV-associated lipodystrophy (93.6%) and congenital deformities (92.2%), and it was lowest in studies investigating patients with acquired deformities (81.5%). Meta-analysis of reported VAS scores resulted in an average score of 7.9 (95% CI, 7.5-8.2), with little variation between the mean scores of individual studies or subgroups ( Figure 4 ).
Surgeon Satisfaction and/or Evaluation
As with patient satisfaction, a very high proportion of the plastic surgeons were satisfied with the result-88.6% (95% CI, 83.4%-92.4%) after a mean follow-up of 1.2 years ( Figure 3 ). The highest overall satisfaction rate was noted in congenital deformities (95.1%), followed by patients with HIVassociated lipodystrophy (89.8%) and acquired deformities (87.1%). The mixed patients displayed the lowest surgeon satisfaction rate (77.8%), though this subgroup consisted of a single study with only 27 patients. Subsequent meta-analysis of VAS scores led to an overall score of 7.8 (95% CI, 7.3-8.3) and similarly to the scores reported by patients, surgeon scores varied little between relevant subgroups (range, 7.3-7.9; Figure 4 ).
Volume Measurements
Twelve studies provided data on volume retention, which was plotted against time in a meta-regression model. Patients with congenital deformities displayed a trend toward gradual decrease, stabilizing at 59.0% (95% CI, 51.1%-64.6%) after 1 year of follow-up ( Figure 5A ). On the contrary, conflicting patterns of volume changes were seen in patients with HIVassociated lipodystrophy, where volume retention decreased to 50.9% (95% CI, 37.2%-66.2%) in some studies and or increased drastically to 238.1% (95% CI, 201.5%-274.3%) in others ( Figure 5B ). 
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Number of AFT Sessions
Meta-analysis of pooled data from 50 studies (1525 patients) showed that a mean of 1.5 sessions (95% CI, 1.3-1.7) were needed to achieve the desired result and on average 27 mL of fat was injected per procedure (eFigure 1 in the Supplement). Subgroup analysis revealed some variation between indications with the highest number of procedures being performed for the correction of congenital deformities (1.8 sessions) and the lowest in HIV-associated facial lipodystrophy (1.1 sessions).
Complications
The incidence of AFT-related clinical complications based on our meta-analysis was low-4.8% (95% CI, 3.3%-6.9%) of the AFT procedures (eFigure 2 in the Supplement). Only in patients with HIV-associated lipodystrophy, a higher rate of complications was reported (6.9%); however, these were not commonly encountered AFT-related complications as in other indications but consisted mainly of asymmetry or overcorrection due to lipohypertrophy.
Discussion
This meta-analysis aims to provide a clinically relevant, quantifiable measure on the overall efficacy of AFT in facial reconstructive surgery. Our results demonstrate a clear trend toward a very-high rate of patient (91.1%) and surgeon (88.6%) satisfaction, confirmed by high satisfaction scores of 7.9 and 7.8, respectively. A successful result was achieved after a mean of 1.5 procedures with a low rate (4.8%) of minor complications. The volume retention in patients with congenital facial deformities showed a wide variation between studies, ranging between 40% to over 80% with pooled effect estimate of 59.0% at 1 year. In patients with HIV-associated lipodystrophy, deviations were even more extreme, and 2 distinct patterns of volume changes were observed. The former resembled the resorption pattern of congenital patients, gradually decreasing to 50.9% at 1 year. The latter, on the other hand, led to a spontaneous increase in volume to more than 238% at 1 year. This could, in theory, be attributed to extreme lipohypertrophy of grafted fat, which has been commonly reported as an adverse event in studies of patients with HIV. Whether this effect is the result of the choice of a donor site affected by lipohypertrophy (cervical hump, abdomen, or breast area), metabolic stimuli or medication must be evaluated in future studies. By a thorough examination of the totality of the evidence, it can be deduced that AFT seems to be an effective procedure that leaves the vast majority of patients and surgeons satisfied with the result after about a year of clinical followup. It is clear that future studies will play a crucial role in providing higher quality evidence that would allow for more nuanced recommendations regarding specific subgroups or indications, evaluating factors influencing the (long-term) volume retention, as well as the added value of supplements. As setting up randomized clinical trials in some of these areas can be difficult, they should be evaluated whenever possible by prospective study design with the use of control groups and validated outcome measurement instruments such as 3-dimensional volume assessments and quality-of-life scales (eTable 6 in the Supplement).
Limitations
The main limitation of this meta-analysis, as well as the accumulated body of knowledge on AFT in general, remains the low level of evidence of published studies. Unlike the widely accepted approach, where the adoption of a new therapy is based on the achievement of statistical significance for the primary outcome from well-executed randomized clinical trials or large cohorts, this has not been possible in the case of AFT. Its unique properties that give it competitive edge above conventional techniques, have also robbed it of an alternative treatment to perform in a control group. Setting up randomized clinical trials with AFT has therefore been difficult owing to practical and Another important obstacle that hinders progress in the field of AFT is the lack of practical and reliable instruments to quantify the absolute effect of treatment. For many years, plastic surgeons have relied on nonvalidated, custom-made questionnaires to measure patient satisfaction and routinely used preoperative and postoperative photographs for a slightly more objective confirmation of the findings. These outcomes have been reported as either continuous (means [SD] ) or categorical (frequencies) variables, based on the type of questionnaire or scale. Each of these presents with its own advantages and limitations. As most retrospective studies rarely measured outcomes preoperatively, determination of the absolute effect of AFT becomes difficult in the absence of baseline values. In addition, the use of a continuous scale is of limited value when attempting to quantify the effect of AFT with different baseline scores. It is arguable that the same change in different satisfaction scores can have different clinical significance. For example, an increase in a satisfaction from 1 to 4 out of 10 can be classified as an unsatisfactory result, while the same increase in another patient from a score of 4 to a score of 7 out of 10 would be seen as successful. When dealing with studies reporting of nominal (categorical) data, outcomes such as the rate of satisfaction are often reported as frequencies of patients falling in each category (eg, dissatisfied, satisfied, very satisfied). As such an approach does not rely on baseline values, it can more accurately reflect the absolute effectiveness of AFT, though it lacks the precision of continuous data.
For the abovementioned reasons, performing a metaanalysis on this topic is highly challenging as the paucity of relevant control groups and preoperative vs postoperative data prevents applying widely accepted statistical measures of effect such as the relative risk or odds ratios. Therefore, this metaanalysis focused on providing pooled effect estimates that indicate the size, direction and confidence intervals for each outcome.
Dealing with heterogeneity is another major challenge with meta-analyses. Pooling a large number of studies with potentially different patient demographics, indications and outcome measurements can result in important heterogeneity that could reduce the validity of the effect estimates. To correct for this, a random-effects model was applied to all cases and whenever possible, subgroup meta-analyses were performed by pooling studies with similar indications together. It is important to note that despite the potential differences between included studies, the pooled effect estimates demonstrate a clear convergence toward a very-high rate of satisfaction with the procedure and a low rate of clinical complications. As the indications of AFT in facial reconstructive surgery consists of a heterogeneous group of indications and patients, it can be argued that such a general approach delivers evidence on precisely the population this meta-analysis aims to draw conclusions about.
Conclusions
Autologous fat transfer seems to be an effective treatment for contour deformities in facial reconstruction, as reflected by the high rate of patient (91.1%) and surgeon (88.6%) satisfaction, confirmed by high satisfaction scores of 7.9 and 7.8, respectively. The desired result was achieved after only 1.5 procedures. Volume retention was observed to decrease to 50% to 60% after 1 year but needs further investigation, especially in patients with HIV-associated facial lipodystrophy. Autologous fat transfer can be considered a safe treatment, with only 4.8% of procedures resulting in minor complications. presented a much needed systematic review and metaanalysis of 52 autologous fat transfer (AFT) studies for facial reconstructive surgery consisting of 1568 patients with the conclusion that there was veryhigh patient satisfaction (91%) and surgeon satisfaction (89%) only after 1.5 sessions with volume retention of 50% to 60% at 1 year.
1 The use of AFT for reconstructive purposes has not been well documented, and this meta-analysis 1 evaluates all of the indications for AFT for facial reconstruction including human immunodeficiency virus (HIV)-associated lipodystrophy (the most common indication), followed by congenital disorders, and then a heterogeneous mixture of trauma, cancer, scars, etc. Volume restoration using AFT has become an integral component to an overall strategy of cosmetic facial rejuvenation over the past 15 years, recognizing that aging consists of deflation, gravity, and rhytidosis. 2 Traditionally, facial reconstruction has used more elaborate techniques to restore soft tissue volume loss like local, regional, and free flaps. With the greater acceptance of AFT for cosmetic cases, fat grafting may increasingly serve as a much needed adjunctive measure to these techniques or as a replacement in many cases where AFT may better achieve the desired cosmesis with the potential for less donor and recipient morbidity. With any surgical method, it is imperative to underscore the attendant risks and limitations that may inform patient consent and affect the final surgical outcome. The review by Krastev and colleagues 3 not only celebrates the success with AFT in diverse reconstructive facial cases but also offers some warranted caution. For example, in cases of HIV-associated lipodystrophy that comprised almost half of the reviewed cases, it was observed that although some patients exhibited a volume decrease to 51% others had a dramatic volume increase to 238% over injected baseline. 3 This unusual development in patients with HIV-associated lipodystrophy has been documented by Sydney Coleman, MD, as well. In the chapter on the subject, this condition is labeled "hamster syndrome" in which 4% of patients with HIVassociated lipodystrophy can suffer progressive, deforming fat hypertrophy recalcitrant to corrective liposuction. 4 Unfortunately, postoperative fat hypertrophy is not necessarily limited only to patients with HIV. Val Lambros, MD, has been perhaps the most vocal commentator of postoperative fat hypertrophy following weight gain.
3 The lesson should be that transplanted fat should not be viewed as a bioinert substance like an off-the-shelf filler. It is metabolically active and a live graft. I have surgically removed discrete globules of fat 10 years after a poorly performed AFT from the periorbital region and from the lips, so proponents that transplanted fat is somehow replaced with scar tissue overtime are misguided in my opinion. In cases where the entire face is overfilled with fat or where individuals have gained weight and the fat has become hypertrophied over time are far harder to treat. In my experience, transplanted fat taken from the thighs and abdomen retain the donor characteristics of fat hypertrophy with weight gain but also the benefit of naturally greater fat retention. Being also a hair transplant surgeon, I have come to hypothesize that the donor dominance of transplanted hair which retains the native characteristics of the donor hair also applies to transplanted fat. Accordingly, I am very careful in soliciting a history of prior weight fluctuations when evaluating patient candidacy for potential AFT. This is one reason why I do not like performing AFT in patients younger than 40 years who may gain weight later in life and in those who have excessive degrees of frequent weight fluctuation (>30 pounds [to convert to kilograms, multiply by 0.45], but less than that for more petite individuals). Furthermore, in general, I do not like performing fat grafting for asymmetric reconstructive cases for fear that the transplanted fat would asymmetrically hypertrophy. On an occasion where I exited the podium after stating this opinion, a colleague of mine confided that he wished he had heard my lecture before he performed a fat transfer into a mandibular defect in a 17-year-old patient where the fat excessively hypertrophied a few years later. I also believe that fat is very difficult to use to correct solitary facial defects be- Eligibility criteria 6 Specify study characteristics (e.g., PICOS, length of follow up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale 5
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